Approved indications: Ajovy is FDA-approved for the preventive treatment of migraine in adults and for the preventive treatment of episodic migraine in pediatric patients 6 to 17 years old who weigh at least 45 kg (99 lb).

Off-label uses: Some clinicians may consider Ajovy off-label for difficult-to-treat headache disorders (such as highly refractory chronic migraine or, less commonly, cluster headache) when standard options fail, but supporting evidence is limited and it is not an established or labeled treatment for these conditions.

Efficacy expectations: In adult clinical trials, patients with episodic migraine had on average about 3 to 4 fewer migraine days per month and those with chronic migraine had about 4 to 5 fewer moderate-to-severe headache days per month compared with baseline, with improvements starting in the first month and maintained with ongoing dosing.

Most people who respond experience fewer and less disabling migraine days rather than complete elimination of attacks, and some may need 2 to 3 months of regular injections before deciding whether the medicine is effective for them.

Comparison to similar drugs: Ajovy is one of several anti-CGRP preventive therapies that show broadly comparable average reductions in migraine days; distinctive features include its option for either monthly or quarterly dosing in adults and a generally low rate of systemic side effects compared with many older oral preventive drugs.

Adult dosing: For preventive treatment of migraine in adults, Ajovy is given by subcutaneous injection as either 225 mg once every month or 675 mg once every 3 months (three 225 mg injections given one after another at different injection sites on the same day).

Pediatric dosing: For episodic migraine in children and adolescents 6 to 17 years old who weigh at least 45 kg (99 lb), the recommended dose is 225 mg by subcutaneous injection once each month.

How to take it: Ajovy is injected under the skin of the abdomen, thigh, or upper arm using a prefilled syringe or autoinjector; injection sites should be rotated and areas that are tender, bruised, scarred, or hardened should be avoided.

It can be given with or without food and at any time of day, but using roughly the same calendar date each month or every 3 months helps maintain consistent protection.

Special instructions: Before injection, remove Ajovy from the refrigerator and let it sit at room temperature for about 30 minutes; do not heat it, shake it, or use it if the solution looks cloudy, discolored, or contains particles.

Patients 13 years and older may self-inject after proper training, while younger children should receive injections from a healthcare provider or a trained adult caregiver.

Missed dose: If a dose is missed, inject it as soon as possible, then schedule future injections based on this new date (1 month later for 225 mg monthly dosing or 3 months later for 675 mg quarterly dosing).

Overdose: If too much Ajovy is injected or doses are given too close together, contact a healthcare provider, emergency services, or a poison control center for advice and observation.

Common side effects: The most frequent problems are injection-site reactions—pain, redness, swelling, itching, or a firm lump—usually mild to moderate, occurring in a substantial minority of patients, and typically appearing within hours to a few days after the shot and resolving without treatment.

Less common side effects can include mild rash or itching away from the injection site, fatigue, or flu-like symptoms.

Serious or rare adverse effects: Serious hypersensitivity reactions, including rash, hives, trouble breathing, and swelling of the face, lips, tongue, or throat (anaphylaxis or angioedema), can occur and require immediate medical attention and permanent discontinuation of Ajovy.

Postmarketing experience has also identified new or worsening high blood pressure and Raynaud’s phenomenon (fingers or toes turning pale, blue, then red and feeling numb, cold, or painful); these symptoms should be evaluated promptly.

Warnings and precautions: Ajovy must not be used in people with a known serious allergy to fremanezumab or any component of the product.

Caution and monitoring are advised in patients with uncontrolled hypertension, significant peripheral vascular disease, or Raynaud’s phenomenon, and in those with a history of severe allergic reactions to biologic medicines.

Data in pregnancy and breastfeeding are limited; decisions to use Ajovy should weigh potential benefits against unknown risks, and a pregnancy registry is available in the United States to collect safety information.

No routine dose adjustment is generally needed for kidney or liver impairment, but experience in severe organ disease is limited.

Safety versus other options: Compared with many traditional oral migraine preventives, Ajovy is less likely to cause sedation, cognitive slowing, or weight gain and has a low potential for drug–drug interactions, though all anti-CGRP agents share a need for vigilance for vascular effects such as high blood pressure and Raynaud’s symptoms.

Reporting side effects and updates: Side effects can be reported to the FDA MedWatch program or to the manufacturer, and current safety information and alerts are available on official FDA and Ajovy websites.

Drug interactions: Ajovy is a monoclonal antibody that is broken down by normal protein pathways rather than liver enzymes, so it has no known clinically significant interactions with most other prescription or over-the-counter medicines, including triptans, NSAIDs, antidepressants, blood pressure medicines, or hormonal contraceptives.

It is commonly used together with acute migraine treatments and, when needed, with other preventive drugs; combining it with other CGRP-targeted therapies (such as other CGRP antibodies or gepant tablets) should be done cautiously and usually under the guidance of a headache specialist.

Supplements, foods, and alcohol: No specific interactions with foods, beverages, or common supplements have been identified, but alcohol and personal migraine trigger foods may still provoke attacks and should be managed individually.

Diagnostic tests and procedures: Ajovy is not known to interfere with routine laboratory tests, imaging studies, or contrast dyes used for X-ray or MRI procedures.

Precautions: Use care in people with uncontrolled hypertension, significant peripheral vascular disease, or Raynaud’s phenomenon, and in those with a history of severe allergic reactions; these patients may need closer monitoring for blood pressure changes and circulation symptoms in fingers and toes.

Discuss use of Ajovy with a clinician if you are pregnant, planning pregnancy, or breastfeeding, or if you have previously had anaphylaxis or angioedema with injectable biologic medicines.

Monitoring needs: Routine blood tests are generally not required, but many clinicians periodically review blood pressure, new or worsening vascular or allergic symptoms, and overall migraine frequency and severity to judge ongoing benefit and safety.

Q: What is Ajovy used for?
A: Ajovy is used to help prevent migraine attacks in adults and to prevent episodic migraine in children and adolescents 6 to 17 years old who weigh at least 45 kg (99 lb); it is not meant to treat a migraine once it has already started.

Q: How long does Ajovy take to start working?
A: Some people notice fewer migraine days in the first month, but it may take 2 to 3 months of regular injections to see the full benefit, and doctors often reassess after several months to decide whether to continue.

Q: Is Ajovy a rescue medicine for migraine pain?
A: No, Ajovy is a preventive medicine given on a fixed schedule to reduce how often migraines occur; you still need separate acute treatments, such as triptans or other pain medicines, to treat individual attacks.

Q: What should I do if I miss a dose of Ajovy?
A: Take the missed injection as soon as you remember, then count your next monthly or quarterly dose from that new date rather than the original schedule, and contact your prescriber if you are unsure how to adjust.

Q: Can I take Ajovy with my other migraine medicines?
A: Ajovy is often used alongside acute migraine drugs and sometimes with other preventive medicines, and because it has few known drug interactions it can usually be combined safely under the guidance of your healthcare provider.

Q: Is Ajovy safe during pregnancy or breastfeeding?
A: The effects of Ajovy in pregnancy and breastfeeding are not well known, so decisions about using it in these situations should be made with your clinician by weighing the potential benefits against the limited safety data, and you may be offered enrollment in a pregnancy registry.

Storage: Store Ajovy in the refrigerator at 36°F to 46°F (2°C to 8°C) in the original carton to protect it from light; do not freeze or shake it.

Ajovy may be kept at room temperature (up to 86°F / 30°C) in the carton for up to 7 days; once it has been at room temperature, do not put it back in the refrigerator, and discard it if not used within 7 days.

Before use: Remove the prefilled syringe or autoinjector from the refrigerator and allow it to reach room temperature for about 30 minutes; keep it out of direct sunlight and do not use hot water, a microwave, or other heat sources to warm it.

Disposal: Each syringe or autoinjector is for one-time use only; after injection, place it immediately into an FDA-cleared sharps disposal container and follow local or pharmacy guidance for discarding the full container—do not throw loose needles or pens into household trash or recycling.

Safety: Keep Ajovy and sharps containers out of the reach of children and pets.